Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
Holding AKRO?
Track your performance easily

Akero Therapeutics (AKRO) Ownership - Who Owns Akero Therapeutics?

468 Followers

Akero Therapeutics (AKRO) Ownership Overview

3.29%25.56%2.26%13.00%55.88%
2.26% Other Institutional Investors
13.00% ETFs
55.88% Public Companies and
Individual Investors
The ownership structure of Akero Therapeutics (AKRO) stock is a mix of institutional, retail, and individual investors. Approximately 40.83% of the company’s stock is owned by Institutional Investors, 3.29% is owned by Insiders, and 55.88% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Sep 13, 2024
xxxxxxxxxxxxx
$16677
Sep 13, 2024
Andrew Cheng
President & Ceo,director
xxxxxxxxxxxxx
$45501
Sep 13, 2024
xxxxxxxxxxxxx
$14870
Sep 13, 2024
xxxxxxxxxxxxx
$16729

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
3,493,159Institution5.03%115,413,973
3,136,370Institution4.52%103,625,665
2,970,761Institution4.28%98,153,943
2,508,425Institution3.61%82,878,362
2,321,101Institution3.34%76,689,177
1,995,635Institution2.87%65,935,780
1,499,897Institution2.16%49,556,597
1,119,702Institution1.61%36,994,954
1,097,082Institution1.58%36,247,589
802,168Insider1.16%26,503,631

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,970,761Institution4.28%98,153,943
2,508,425Institution3.61%82,878,362
2,321,101Institution3.34%76,689,177
1,995,635Institution2.87%65,935,780
753,408Institution1.09%24,892,600
732,719Institution1.06%24,209,036
722,363Institution1.04%23,866,874
542,464Institution0.78%17,923,011
470,835Institution0.68%15,556,388
450,880Institution0.65%14,897,075

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,861,758Institution2.67%61,512,484
1,940,926Institution2.78%55,685,167
1,016,126Institution1.46%35,005,541
958,666Institution1.37%27,504,128
545,818Institution0.78%18,033,827
406,586Institution0.58%13,433,601
306,099Institution0.44%10,545,111
311,013Institution0.45%8,922,963
228,454Institution0.33%7,548,120
161,377Institution0.23%4,629,906

FAQ

Who Owns Akero Therapeutics Inc (AKRO)?
According to the latest TipRanks data, approximately 2.26% of the company's stock is held by institutional investors, 3.29% is held by insiders, and 55.88% is held by retail investors.
    What percentage of Akero Therapeutics Inc (AKRO) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 2.26% of Akero Therapeutics Inc (AKRO) stock is held by institutional investors.
      What percentage of Akero Therapeutics Inc (AKRO) stock is held by retail investors?
      According to the latest TipRanks data, approximately 55.88% of Akero Therapeutics Inc (AKRO) stock is held by retail investors.
        Who owns the most shares of Akero Therapeutics Inc (AKRO)?
        Vanguard owns the most shares of Akero Therapeutics Inc (AKRO).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis